Viracta Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viracta therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viracta Therapeutics Today - Breaking & Trending Today

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Announces Sale of Priority Review Voucher for $108 Million
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Laura Cooper , Head Of Communications , Drug Administration , Exchange Commission , Viracta Therapeutics Inc , Rare Pediatric Disease Priority Review Voucher Program , One Biopharmaceuticals , Priority Review Voucher , Day One , Charles York , Viracta Therapeutics , Private Securities Litigation Reform Act , Sci Advisors ,

Day One Announces Sale of Priority Review Voucher for $108

Day One Announces Sale of Priority Review Voucher for $108
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Laura Cooper , Exchange Commission , Drug Administration , Head Of Communications , Viracta Therapeutics Inc , Rare Pediatric Disease Priority Review Voucher Program , One Biopharmaceuticals , Priority Review Voucher , Day One , Charles York , Viracta Therapeutics , Private Securities Litigation Reform Act , Sci Advisors ,

Viracta Therapeutics (NASDAQ:VIRX) Price Target Cut to $11.00

Viracta Therapeutics (NASDAQ:VIRX – Free Report) had its price target decreased by Oppenheimer from $13.00 to $11.00 in a report released on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $4.00 price objective on shares of Viracta Therapeutics in a […] ....

Viracta Therapeutics Inc , Viracta Therapeutics , Free Report , Get Free Report , Viracta Therapeutics Daily ,

Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $11.00 at Oppenheimer

Viracta Therapeutics (NASDAQ:VIRX – Free Report) had its price target lowered by Oppenheimer from $13.00 to $11.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $4.00 target price on shares of Viracta Therapeutics […] ....

Viracta Therapeutics Inc , Viracta Therapeutics , Free Report , Get Free Report , Viracta Therapeutics Daily ,

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces New Employment Inducement Grants
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Ashleigh Barreto , Head Of Investor Relations Corporate Communications , Viracta Therapeutics Inc , Michael Faerm , Chief Financial Officer , Equity Incentive , Equity Incentive Plan , Inducement Plan , Nasdaq Listing Rule , Viracta Therapeutics , Relations Contact , Investor Relations ,